Shionogi Presents Real-World Evidence Showing Strong Efficacy with Fetroja® (cefiderocol) Against Treatment Resistant Bacterial Infections at IDWeek 2022
businesswire.com
news
2022-10-19 00:00:00

October 19, 2022 08:00 AM Eastern Daylight Time FLORHAM PARK, N.J.--(BUSINESS WIRE)--Shionogi Inc., the United States subsidiary of Shionogi & Co., Ltd., announced that new Fetroja® (cefiderocol) data will be presented at IDWeek 2022 including new real-world evidence demonstrating Fetroja's strong efficacy against some of the most difficult-to-treat Gram-negative bacterial infections.



New data from PROVE (Retrospective Cefiderocol Chart Review) demonstrated that Fetroja achieved clinical cure in 63% (48/76) of patients with Acinetobacter baumannii infections and 63% (76/120) of patients with Pseudomonas aeruginosa infections.
